A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population

Table 1 Description of cases screened for BRCA1 and BRCA2 mutations

Group (Period of ascertainment, years)	Histological subtype ¹	Number of women with ovarian cancer (fallopian tube ² and primary peritoneal cancers)	Tumour grade				Disease stage ³				Mean age of diagnosis (range), years
Group (Period of ascertainment, years)	Histological subtype ¹		G1	G2	G3	Un-classified	I	II	III	IV	Mean age of diagnosis (range), years
All (1997–2011)	Serous	369 (9)	12	62	279	16	25	28	275	40	61 (24 – 91)
	Endometrioid	30 (0)	0	20	9	1	13	2	14	1	58 (41 – 82)
	Mixed cell	32 (0)	0	11	21	0	6	2	21	3	57 (36 – 77)
	Undifferentiated	8 (1)	1²	0	3	4	2	0	6	0	61 (33 – 72)
	All types	439 (10)	13	93	312	21	46	32	316	44	61 (24 – 91)
Subgroup (2006–2008)	Serous	92 (4)	3	11	73	5	7	8	68	9	61 (38 – 82)
	Endometrioid	9 (0)	0	7	2	0	6	1	2	0	58 (41 – 82)
	Mixed cell	12 (0)	0	2	10	0	3	1	6	2	60 (40 – 77)
	Undifferentiated	3 (1)	1²	0	1	1	1	0	2	0	68 (62 – 71)
	All types	116 (5)	4	20	86	6	17	10	78	11	61 (38 – 82)

¹Mixed cell has components of serous subtype cancer cells; ²fallopian tube adenocarcinoma; ³staging information was not available for a women with a serous ovarian carcinoma diagnosed at 91 years of age.

ISSN: 1757-2215